| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 9.000 +22.22% on 02/19/26 | | 11.400 -3.51% on 03/10/26 | +1.750 (+18.92%) since 02/10/26 |
| 3-Month | 7.500 +46.67% on 01/21/26 | | 11.400 -3.51% on 03/10/26 | +0.303 (+2.83%) since 12/10/25 |
| 52-Week | 7.500 +46.67% on 01/21/26 | | 18.500 -40.54% on 08/19/25 | +0.500 (+4.76%) since 03/10/25 |
Ondine Biomedical (OBI:LON), a Canadian life sciences company, reported that photodisinfection being developed for food processing demonstrated high efficacy against key food-borne pathogens. Results of...
Ondine Biomedical Inc. (LON: OBI) presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33 rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in...
One of Canada’s top research hospitals, The Ottawa Hospital, has presented results from its 2022 quality improvement study into patient outcomes after spinal surgery when using nasal photodisinfection...
The study, published in Frontiers in Cellular and Infection Microbiology , 1 met its primary endpoint, with a highly significant decrease in viral infectivity recorded as early as two days after treatment...
Research presented at the PDT-PDD Conference in Nancy, France showed that a large food processing plant in Manitoba, Canada, was able to reduce the rate of COVID-19 amongst its employees following the...
Results show a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in...
/PRNewswire/ -- Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is...
/CNW/ -- Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating...
| 3rd Resistance Point | 12.667 |
| 2nd Resistance Point | 12.033 |
| 1st Resistance Point | 11.517 |
| Last Price | 11.000 |
| 1st Support Level | 10.367 |
| 2nd Support Level | 9.733 |
| 3rd Support Level | 9.217 |
| 52-Week High | 18.500 |
| Fibonacci 61.8% | 14.298 |
| Fibonacci 50% | 13.000 |
| Fibonacci 38.2% | 11.702 |
| Last Price | 11.000 |
| 52-Week Low | 7.500 |